Malignant Brain Tumors
Conditions
Keywords
adult glioblastoma multiforme, adult anaplastic astrocytoma, adult anaplastic astrocytoma/Mixed
Brief summary
RATIONALE: Current therapies for adults with primary malignant brain tumors that have not responded to standard therapy provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of adults with primary malignant brain tumors that have not responded to standard therapy. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on adults with primary malignant brain tumors that have not responded to standard therapy.
Detailed description
OBJECTIVES: * To determine the efficacy of Antineoplaston therapy in patients with primary malignant brain tumors that have not responded to standard therapy, as measured by an objective response to therapy (complete response, partial response or stable disease). * To determine the safety and tolerance of Antineoplaston therapy in patients with a primary malignant brain tumor. OVERVIEW: This is a single arm, open-label study in which adults with malignant brain tumors that have not responded to standard therapy receive gradually escalating doses of intravenous Antineoplaston therapy (Atengenal + Astugenal) until the maximum tolerated dose is reached. Treatment continues for at least 12 months in the absence of disease progression or unacceptable toxicity. After 12 months, patients with a complete or partial response or with stable disease may continue treatment. To determine objective response, tumor size is measured utilizing MRI scans, which are performed every 8 weeks for the first two years, every 3 months for the third and fourth years, every 6 months for the 5th and sixth years, and annually thereafter. PROJECTED ACCRUAL: A total of 20-40 patients will be accrued to this study
Interventions
DRUGAntineoplaston therapy (Atengenal + Astugenal)
Adults with a primary malignant brain tumor that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal). The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Sponsors
Burzynski Research Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed incurable adult primary malignant brain tumor * Evidence of progressive or recurrent tumor by MRI scan performed within 2 weeks prior to study entry * Must have received and failed standard therapy * Tumor must be at least 5 mm * No brain stem tumors PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * Karnofsky 60-100% Life expectancy: * At least 2 months Hematopoietic: * Hematological function normal * WBC at least 2000/mm\^3 * Platelet count at least 50,000/mm\^3 Hepatic: * No liver failure * No evidence of hepatic insufficiency * Bilirubin no greater than 2.5 mg/dL * SGOT/SGPT no greater than 5 times upper limit of normal Renal: * No evidence of renal insufficiency * Creatinine no greater than 2.5 mg/dL * No history of renal conditions that contraindicate high dosages of sodium Cardiovascular: * No uncontrolled hypertension * No history of congestive heart failure * No chronic heart failure * No other cardiovascular conditions that contraindicate high dosages of sodium Pulmonary: * No serious lung disease, such as severe chronic obstructive pulmonary disease Other: * Not pregnant or nursing * Fertile patients must use effective contraception during and for 4 weeks after study participation * No medical or psychiatric illness that would preclude study treatment * No active infection PRIOR CONCURRENT THERAPY: Biologic therapy: * At least 4 weeks since prior immunotherapy * No concurrent immunomodulating agents Chemotherapy: * At least 4 weeks since prior chemotherapy, except in patients with disease progression during initial therapy * At least 6 weeks since prior nitrosoureas, except in patients with disease progression during initial therapy * No concurrent antineoplastic agents Endocrine therapy: * Corticosteroids allowed Radiotherapy: * See Disease Characteristics * At least 8 weeks since prior radiotherapy, except in patients with disease progression during initial therapy Surgery: * At least 4 weeks since prior surgery, except in patients with disease progression during initial therapy Other: * Recovered from prior therapy * Cytodifferentiating agents allowed
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Objective Response | 12 months | Objective response rate per Response Assessment in Neuro-Oncology (RANO) for target lesions and assessed by MRI: Complete Response (CR), disappearance of all disease sustained for at least four weeks; Partial Response (PR), \>=50% decrease in the sum of the products of of the greatest perpendicular diameters of all measurable enhancing lesions, sustained for at least four weeks. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Who Survived | 6 months, 12 months, 24 months, 36 months, 48 months, 60 months | 6 months, 12 months, 24 months, 36 months, 48 months, 60 months overall survival |
Countries
United States
Participant flow
Recruitment details
Fourty patients were recruited between February 1996 and February 2011. All study subjects were seen at the Burzynski Clinic in Houston TX
Participants by arm
| Arm | Count |
|---|---|
| Antineoplaston Therpay Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
Adults with a primary malignant brain tumor that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal). | 40 |
| Total | 40 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Not evaluable | 13 |
Baseline characteristics
| Characteristic | Antineoplaston Therpay |
|---|---|
| Age, Continuous | 48.2 Years |
| Sex: Female, Male Female | 14 Participants |
| Sex: Female, Male Male | 26 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 40 / 40 |
| serious Total, serious adverse events | 21 / 40 |
Outcome results
Primary
Number of Participants With Objective Response
Objective response rate per Response Assessment in Neuro-Oncology (RANO) for target lesions and assessed by MRI: Complete Response (CR), disappearance of all disease sustained for at least four weeks; Partial Response (PR), \>=50% decrease in the sum of the products of of the greatest perpendicular diameters of all measurable enhancing lesions, sustained for at least four weeks.
Time frame: 12 months
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Antineoplaston Therpay | Number of Participants With Objective Response | Complete Response | 2 Participants |
| Antineoplaston Therpay | Number of Participants With Objective Response | Partial Response | 2 Participants |
| Antineoplaston Therpay | Number of Participants With Objective Response | Stable Disease | 4 Participants |
| Antineoplaston Therpay | Number of Participants With Objective Response | Progressive Disease | 19 Participants |
Secondary
Percentage of Participants Who Survived
6 months, 12 months, 24 months, 36 months, 48 months, 60 months overall survival
Time frame: 6 months, 12 months, 24 months, 36 months, 48 months, 60 months
Population: All study subjects receiving any Antineoplaston therapy
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Antineoplaston Therpay | Percentage of Participants Who Survived | 6 months overall survival | 47.5 Percentage of participants |
| Antineoplaston Therpay | Percentage of Participants Who Survived | 12 months overall survival | 27.5 Percentage of participants |
| Antineoplaston Therpay | Percentage of Participants Who Survived | 24 months overall survival | 2.5 Percentage of participants |
| Antineoplaston Therpay | Percentage of Participants Who Survived | 36 months overall survival | 2.5 Percentage of participants |
| Antineoplaston Therpay | Percentage of Participants Who Survived | 48 months overall survival | 2.5 Percentage of participants |
| Antineoplaston Therpay | Percentage of Participants Who Survived | 60 months overall survival | 2.5 Percentage of participants |